Professor Richard Scolyer completes 250th Parkrun, a goal set after cancer diagnosis
The renowned melanoma researcher was among hundreds of runners who took part in the Greenway Parkrun at Haberfield in Sydney's inner west on Saturday morning.
Professor Scolyer, who put himself forward as "patient zero" for revolutionary brain cancer treatment, crossed the finish line to applause and cheers from the crowd.
Shortly after he finished the race, light rain began to fall and a rainbow formed over the reserve.
When speaking to the media, he said 250 Parkruns was a "big goal" he set for himself.
"I did a lot of Parkruns in the early 2000s but then as the kids go through various parts of their life you stop doing it," he said.
"And then when I got sick again I wanted to try and get to 250.
"I guess it's part of my personality. Bit embarrassing, but wanting to get to 250 was something that pushed me along."
Professor Scolyer said it was "crazy" to see such a huge turnout at the run and that he was "very happy" to complete his goal.
Professor Scolyer said he had doubts about whether he would reach the major milestone.
"To be honest, I never thought I'd get there," he said.
In a post to his more than 20,000 followers on X earlier this week, he wrote that it was a goal "I wasn't sure I'd reach" and that he was excited to be able to take part in the run.
"So it's with a huge amount of gratitude to my family, friends, and medical team that I'll be celebrating this achievement," he said.
The post on social media came after a long period of no updates, which Professor Scolyer said was due to the impact of his latest round of cancer treatment, but that he now felt "like the fog has lifted a bit".
Professor Scolyer was diagnosed with an aggressive glioblastoma in 2023 and was given just six to eight months to live.
But an experimental immunotherapy treatment he was given managed to keep the cancer at bay for almost two years with no recurrence.
However, he revealed in March that after undergoing scans, he had received the heartbreaking news that his brain cancer had come back.
In May, he had another setback, revealing that his first proper scan since the surgery showed the glioblastoma had progressed and it was getting "harder to treat".
He told ABC News Breakfast last month he wasn't sure how much time he had left.
"I'm still here and still able to chat to you so I'm pretty pleased about that," he said. "Who knows how long I've got. Could be months, could be less."
Professor Scolyer said he's focused on spending the time he has left doing the things he loves most.
"I love my life. I love the interactions I have with so many people.
"I guess in reality, I have focused down on the things that I like doing. Spending more time with my family is number one, but also contributing to society. It's something I've done for a long, long time.
"I've been a specialist for more than 25 years now. So a lot of things that I've done I don't want to give up just like that."
Professor Scolyer has been very public and honest about his prognosis and journey through brain cancer treatment in interviews, social media and in his recent memoir, Brainstorm.
His memoir, which was co-written with Garry Maddox, won the Social Impact Book of the Year at the Australian Book Industry Awards in Melbourne last month.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
8 hours ago
- ABC News
SA's toxic algal bloom expected to be long-lasting
South Australia's toxic algal bloom has caused a deluge of marine deaths along the state's coast. Reporter Leah MacLennan sat down with Environment Minister Susan Close to ask her how long it may last, and what can be done to help.
News.com.au
11 hours ago
- News.com.au
Scott Power: ASX health lifts to start FY26, Tetratherix ends IPO drought
ASX health up 1.6% over five days as Morgans' Scott Power says the mood is positive for start of FY26 Wound management house Tetratherix make its ASX debut and breaks an IPO drought for sector ProMedicus surges past $300 for first time following two new US customer contracts worth a total $190 million Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. Morgans' senior healthcare analyst Scott Power has started FY26 in an optimistic mood, noting that despite the global geopolitical and economic uncertainties of recent months, the market broadly has been powering through and hitting new highs across many sectors. He noted healthcare was the laggard, with the S&P/ASX 200 Health Care Index falling 1.05% in June and down 6.64% YTD but said there was money flowing into the market more broadly. "If you look across the market there's multiple capital raisings going on across different sectors," he said. "That is suggesting people are feeling more confident and putting money to work." Wound management house Tetratherix (ASX:TTX) made its ASX debut on Monday breaking an IPO drought for the sector and trading up to 13% above their $2.88 a share offer price. Tetratherix is the first life sciences IPO since late November 2024, when cryogenics play Vitrafy Life Sciences (ASX:VFY) and nerve repair house ReNerve (ASX:RNV) listed on the same day. Barrenjoey Markets and Morgans Financial were joint lead managers and underwriters to the Tetratherix IPO. The S&P/ASX 200 Health Care index (ASX:XHJ) was up 1.6% for the past five days, while the benchmark S&P/ASX 200 (ASX:XJO) rose 0.6% for the past five days. "Over the past couple of months it has been pretty downbeat but it certainly feels a lot more upbeat, particularly since the end of the financial year and all the tax loss selling out of the way," Power said. ProMedicus surges past $300 on contract wins Health imaging stock ProMedicus (ASX:PME) surged ~10% on Thursday to rocket past $300 for the first time after announcing two new US customer contracts worth a total $190 million. The first win is a $170 million, 10-year contract with Colorado-based UCHealth, for the company's suite of image viewing and storage tools. The deal expands Promedicus into cardiology imaging, one of the adjacent 'ologies' the company had been targeting. UCHealth is a Colorado-based network of 14 hospitals, with affiliate clinics extending into Wyoming and Nebraska. Louisiana-based Franciscan Missionaries of Our Lady Health also renewed an existing contract for $20m, over five years. The deal renews a contract for the company's Visage 7 viewer, at a higher per-transaction fee. It also provides the merciful missionaries with Visage 7 Open Archive, which offers 'best-in-class interoperability'. The UCHealth contract is ProMedicus' largest deal to date and follows a $330m, 10-year agreement signed in November with Trinity Health, one of the largest not-for-profit healthcare systems in the US. "This company just goes from strength to strength and with the share price currently above $300 it has more than recovered from the wobbles it had in April when US President Donald Trump announced the tariffs," Power said. Morgans maintains a trim rating on ProMedicus and increased its 12-month target price from $250 to $280. "We view PME as one of the highest quality businesses on the ASX with high margins and long contracted revenue base, providing significant baseline earnings support," healthcare analyst Iain Wilkie wrote in a note to client. "We have a DCF valuation of A$280 p/s and with shares trading above this level, we advocate for active investors to TRIM overweight positions." Power's Powerplay – Micro X pivots to focus on medical applications Leader in cold cathode x-ray technology for health and security markets Micro-X (ASX:MX1) is Power's pick of the week. Power said the company had recently raised capital, added a strategic investor and realigned its business to focus on medical imaging, deprioritising security and defence. He said the realignment made sense and the business was funded to execute on the strategy. "It's early days in the realignment and customer receipts from imaging are still modest, although a major US hospital is evaluating the Rover+ mobile x-ray unit which could result in material sales over time," he said. Morgans has a speculative buy rating on Micro X and 12-month target price of 17 cents. Underperformers selling up assets Power said there were underperforming companies across the ASX healthcare sector, which were looking to, or have managed to, sell their primary assets. He said examples were Next Science (ASX:NXS) and MedAdvisor (ASX:MDR). Next Science has entered a binding asset purchase agreement to sell substantially all its assets for US$50m to Demetra, an Italian based healthcare company. The directors have unanimously recommended shareholders vote in favour of the proposed transaction. Assuming the transaction is completed at an EGM on August 14 and after repayment of debts and other costs, NXS will distribute remaining funds to shareholders estimated to be US$30m (~15 cents per share). MedAdvisor has entered into a binding share sale and purchase agreement to sell its ANZ business division and associated intellectual property to Jonas Software AUS Pty Ltd – part of multinational Constellation Software for $35m. "In both cases from a share price perspective they have significantly underperformed for a long time and the decision has been made, in my opinion correctly, to find a buyer," Power said. "Albeit, shareholders will have lost money but it's better to at least get something rather than let the value of the business deteriorate more. "I wouldn't be surprised if there are more companies which follow that path as across the life science sector there has been dozens of companies which have had massive share price underperformance." EMVision makes progress on key trials EMvision Medical Devices (ASX:EMV) announced this week five of the six sites were now enrolling and scanning patients in the pivotal validation trial for its first commercial device – the emu point-of-care bedside brain scanner for stroke diagnosis. EMVision said the site initiation visit and device training at the third US site for the pivotal trial – designed to support US Food and Drug Administration (FDA) de novo (new device) clearance for emu – at the Mount Sinai site in New York was a success, with recruitment underway. The sixth and final site, on the west coast of the US, for the pivotal trial is expected to be announced shortly. The trial has an estimated enrolment period of 6-12 months, followed by analysis and reporting of the clinical data. EMVision said in parallel it was also undertaking cost-effective strategy for continued device innovation, algorithm enhancement and data to support indication expansion to traumatic brain injury. Referred to as EMVision's Continuous Innovation Study the initiative has received ethics approval received to start scanning patients with suspected stroke or traumatic brain injury at Brisbane's Princess Alexandra Hospital and John Hunter Hospital in Newcastle shortly. "EMVision is making good progress," Power said. Neurizon signs global licensing deal with NYSE-listed Elanco Neurizon Therapeutics (ASX:NUZ) has entered an exclusive global licensing deal with New York Stock Exchange-listed Elanco Animal Health Incorporated and affiliates for monepantel, the active pharmaceutical ingredient in its lead drug NUZ-001. Neurizon said the licensing deal strengthen its strategic outlook for development, manufacturing and potential future commercialisation of NUZ-001, which is in development for the most common form of motor neurone disease (MND) called amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company said the licensing agreement also strengthens its regulatory position by providing ongoing access to essential animal safety and manufacturing data — both critical pillars for advancing clinical trials, securing potential regulatory approvals, and enabling global market entry. In a note to client Wilkie said Neurizon was a strong proposition in the rare disease space with significant near-term catalysts in a condensed timeframe and precedent for an accelerated approval pathway. "While considerable clinical risk remains, we view NUZ-001 as a drug with a sound scientific basis in ALS, strong safety profile, and promising hint of potential efficacy above existing treatments," he wrote. Morgans has a speculative buy rating on Neurizon and 12-month target price of 42 cents. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While EMVision and Neurizon are Stockhead advertisers, the companies did not sponsor this article.
ABC News
15 hours ago
- ABC News
Flu cases, hospitalisations on the rise as SA government urges for more vaccinations
Reported flu cases across South Australia have spiked 70 per cent this year, according to government data, prompting fears about the health system's capacity to cope with more hospital presentations. The state government released data on Friday showing there had been 10,569 reported flu cases so far in 2025, up from 6,212 at the same time last year. It comes after a total of 1,627 new flu cases were reported in the past week, which is almost the highest number of cases reported in any week for the past five years, according to the government. The number of people hospitalised due to the flu has also increased to 1,042 this year, compared to 673 at this point last year. Health Minister Chris Picton said the flu case spike was causing two problems: an increase in hospital presentations and more health workers taking sick leave. "We have seen a spike in hospitalisations and significantly more hospitalisations because of the flu than the same time last year," Mr Picton said. "And also, we've seen more absences in terms of many of those workplaces because the workers themselves have the flu." Mr Picton said workplace flu absences were affecting GPs, doctors, and aged care workers. He said there had "never been a more important time to make sure that you're vaccinated for flu". "That's why we're focusing our efforts particularly in terms of young kids, but also older people and people who have chronic health conditions." South Australia's take-up of the flu vaccine is the highest of any mainland states at 32.1 per cent of the population, according to the state government. That is higher than Victoria at 29.9 per cent, New South Wales at 26.8 per cent and Western Australia and Queensland at 25.8 per cent, the government said. The flu spike comes as the state's hospital system continues to struggle with demand. Ambulance ramping hours soared to their third-highest level on record in May, with patients spending 4,791 hours waiting outside public hospitals for treatment. The data, the most recent released by the state government, was taken before the onset of winter and the spike in flu cases Last year's winter saw ambulance ramping reach record levels, with the paramedic's union fearing 2025 will be even worse. Paul Ekkelboom, general secretary of the Ambulance Employees Association (AEA), said the flu figures were "alarming". "History tells us it's only going to get worse from here," he said, adding it was "only a month into winter". "It's placing a huge strain on our health system, every winter there is an increase in the demand and this includes flu cases." Mr Ekkelboom said "from all accounts" ramping hours were going up, adding that ambulance crews were dealing with fatigue and burnout. "We are concerned it's only a matter of time before this situation, where demand can't be met, results in negative patient outcomes," he said.
